Vertex announces positive phase 2 data in third proof-of-concept study
Vertex announced positive results of a Phase 2 study of investigational NaV1.8 inhibitor VX-150 in patients with pain caused by small fiber neuropathy. The study met its primary endpoint and showed treatment with VX-150 demonstrated statistically significant and clinically meaningful pain reduction. December 18, 2018